News & Press Releases

Integrity Applications Signs Two Additional Distribution Agreements for Its GlucoTrack® Model DF-F Glucose Monitoring Device

March 22nd, 2014

Integrity Applications Signs Two Additional Distribution Agreements for Its GlucoTrack® Model DF-F Glucose Monitoring Device

GlucoTrack® Will Be Available in the Philippines and Chile 

ASHKELON, Israel – March 20, 2014 — Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into distribution agreements for the GlucoTrack device in the Philippines and in Chile. According to the International Diabetes Federation, a total of about 3.3 million people with diabetes, or 6 percent of the adult population, live in the Philippines, and a total of about 1.3 million people with diabetes, or 10.4 percent of the adult population, live in Chile. This is its second distribution agreement in Asia and the second distribution agreement in South America.

The agreement in the Philippines became effective on March 11, 2014 and the one in Chile becomes effective on April 13, 2014. Based on the minimum purchase forecasts contained in these distribution agreements, Integrity Applications anticipates that these distributors will purchase from it an aggregate of about $1.6 million of GlucoTrack model DF-F devices in the first 12 months of sales.

Avner Gal, President and CEO of Integrity Applications, said, “These distribution agreements reinforce that there is global need and demand for GlucoTrack. With our recent extended CE Mark approval to six-month calibration validity, we believe GlucoTrack DF-F offers users yet another important advantage to using our device, and are continuing to market GlucoTrack to additional distributors who can offer our new, noninvasive option for monitoring blood glucose to diabetes patients.”

GlucoTrack features a small sensor that clips to the earlobe and measures the wearer’s blood glucose level by taking measurements using three technologies. The measurements are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived blood glucose measurement is also announced verbally, making it suitable for the elderly and vision-impaired diabetes patients. The company has obtained a CE Mark for its GlucoTrack Model DF-F in Europe (June 2013) and intends to seek Food and Drug Administration approval for GlucoTrack in the United States.

To watch a video detailing the benefits of GlucoTrack, please visit the following link: http://www.integrity-app.com/the-glucotrack/

About GlucoTrack®

GlucoTrack features a small sensor that clips to the earlobe and measures the wearer’s blood glucose level by taking measurements using three technologies. The measurements are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived blood glucose measurement is also announced verbally, making it suitable for the elderly and vision-impaired diabetes patients. The company has obtained a CE Mark for its GlucoTrack Model DF-F in Europe (June 2013) and intends to seek Food and Drug Administration approval for GlucoTrack in the United States.

To watch a video detailing the benefits of GlucoTrack, please visit the following link: http://www.integrity-app.com/the-glucotrack/

About Integrity Applications, Inc.

Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty or discomfort of conventional (invasive) spot finger stick devices. Integrity Applications works primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information please visit www.integrity-app.com.

 

Forward-Looking Statements

 

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect,” and “will,” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to successfully commercialize the GlucoTrack DF-F; the ability of the GlucoTrack DF-F to achieve acceptable pricing, adequate third party reimbursement or market acceptance; the ability of Integrity Applications to manage its growth and the expansion of its operations to include commercialization activities; risks relating to the use of third party manufacturers; risks relating to the development of Integrity Applications’ sales, marketing and distribution capability, either on its own or through collaborations with marketing partners; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012.

 

Contact:

 

Integrity Applications
Avner Gal, +972 (8) 675-7878
President and CEO
info@integrity-app.com
or
Dian Griesel Int’l.
Investor Relations:

Cheryl Schneider

cschneider@dgicomm.com
Public Relations:

Susan Forman

sforman@dgicomm.com

or

Laura Radocaj

lradocaj@dgicomm.com
+1 (212) 825-3210

 

Back to all news & press releases

Sign up to our newsletter
To receive occasional news updates

LinkedIn Facebook Twitter